Related coverage linked through entity extraction aliases.
May 17, 2026
Ebola Virus Disease remains a public health concern due to its high fatality rate. A new outbreak has been confirmed in Congo’s Ituri province, while early treatment and approved monoclonal antibodies can enhance survival.
May 17, 2026
ImmunityBio said the Saudi FDA encouraged submission of a regulatory package for recombinant BCG and opened talks on expanding ANKTIVA with checkpoint inhibitors to additional tumor types. The company expects to file the rBCG package within weeks.
May 09, 2026
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
May 04, 2026
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
May 04, 2026
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
May 02, 2026
Laguna won FDA Breakthrough Device Designation for a blood-based schizophrenia test, while Neurocrine dosed the first patient in a Phase 2 trial of NBI-1117570.
Apr 25, 2026
WHO has prequalified Coartem Baby, the first malaria treatment developed for newborns and young infants weighing 2 to 5 kilograms. The decision opens access through public procurement and donor-funded programs.
Apr 23, 2026
WHO in January 2024 launched its first list of priority childhood cancer drug formulations, naming six medicines that still lack optimal child-friendly versions. The agency says about 400,000 children and adolescents develop cancer each year and is working to expand access to safe, effective paediatric formulations.
Apr 22, 2026
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
Apr 20, 2026
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Apr 17, 2026
The FDA granted Breakthrough Device Designations to NG-TEST® Candida auris and NG-TEST® Acineto-5®, two rapid assays targeting critical drug-resistant pathogens. Both tests deliver results within 15 minutes and are currently available for Research Use Only while FDA review continues.
Apr 13, 2026
Neurocrine Biosciences initiated and dosed the first patients in a Phase 2 trial of NBI-1117570 in adults with schizophrenia. Nxera Pharma said it will receive US$22.5 million in milestone payments to be recognised as Q1 FY2026 revenue.
Apr 13, 2026
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Apr 08, 2026
NanoViricides has filed regulatory applications for its antiviral candidate NV-387, seeking both Rare Pediatric Disease Drug Designation for measles treatment and Orphan Drug Designation for both measles and MPox treatments. The company could qualify for significant incentives including tax credits, fee exemptions, market exclusivity, and potentially a Priority Review Voucher worth approximately $160 million. There are currently no approved drugs for treating either measles or MPox, with both diseases showing concerning case trends.
Apr 07, 2026
Bangladesh has launched an emergency measles vaccination campaign targeting over one million children as a deadly outbreak spreads across 56 districts. The outbreak has caused at least 17 confirmed deaths with 113 suspected fatalities and over 7,500 infections. The campaign prioritizes children aged six months to five years in high-risk areas amid concerns about critical immunity gaps and overwhelmed healthcare facilities.
Apr 07, 2026
GC Biopharma said a review paper in Human Vaccines & Therapeutics analyzed more than 40 studies on its MAV/06 varicella vaccine strain. The paper summarized 30 years of data showing 99-100% neutralizing antibody rates and adverse event incidence of 0.41 to 0.57 cases per 100,000 doses.
Apr 01, 2026
A study finds most children with enterovirus meningitis have favorable long-term outcomes, with only 8.9% experiencing adverse sequelae. Meanwhile, global data shows 259,000 meningitis deaths in 2023, with children under 5 accounting for over one-third of fatalities. Non-polio enteroviruses were the leading cause of meningitis cases worldwide.
Apr 01, 2026
The World Health Organization has released INN Proposed List 134 in January 2026, disclosing non-proprietary names and structures for investigational drugs. This follows earlier lists published in July 2025 (List 133) and February 2025 (List 132), providing comprehensive data on drug candidates in development.
Mar 24, 2026
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Mar 23, 2026
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
